Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

November 29, 2022

https://www.globenewswire.com/news-release/2022/11/29/2563848/0/en/Atea-Pharmaceuticals-Announces-First-Patient-Dosed-in-SUNRISE-3-Phase-3-Registrational-Trial-of-Bemnifosbuvir-an-Investigational-Oral-Antiviral-for-the-Treatment-of-COVID-19.html

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status

Read more at globenewswire.com

Related news for (AVIR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.